Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 {(R)-2-[4-(quinolin-2-yl-methoxy) phenyl]-2-cyclopentyl acetic acid} and structurally …

A Hatzelmann, R Fruchtmann, KH Mohrs… - Biochemical …, 1993 - Elsevier
… t Miiller-Peddinghaus R, Kohlsdorfer C, Theissen-Popp P, Fruchtmann R, Perzborn E,
Beckermann B, Biihner K, Ahr HJ and Mohrs KH, BAY X 1005, a new inhibitor of leukotriene …

Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase

A Hatzelmann, R Fruchtmann, KH Mohrs, S Raddatz… - Agents and Actions, 1994 - Springer
Five-lipoxygenase (5-LOX) inhibition is gaining increasing importance as a novel approach
to therapy of allergic asthma and other inflammatory diseases. Presently, two types of …

Efficient asymmetric synthesis of β-amino acid BAY 10-8888/PLD-118, a novel antifungal for the treatment of yeast infections

J Mittendorf, J Benet-Buchholz, P Fey, KH Mohrs - Synthesis, 2003 - thieme-connect.com
The β-amino acid BAY 10-8888/PLD-118 is currently being investigated in phase II clinical
studies as a novel antifungal for the treatment of yeast infections. An efficient asymmetric …

In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis

R Fruchtmann, KH Mohrs, A Hatzelmann, S Raddatz… - Agents and actions, 1993 - Springer
… a carboxylic group facilitated oral activity; the variation of the lipophilic side chain and the
shift from the meta to the para position further increased the in vitro and in vivo potency (Mohrs

BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics.

…, B Beckermann, K Bühner, HJ Ahr, KH Mohrs - … of Pharmacology and …, 1993 - ASPET
(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) (BAY X1005) is an orally
active inhibitor of the synthesis of the leukotrienes B4 and C4 in selected animal models that …

Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system—implications for …

…, J Goossens, R Fruchtmann, KH Mohrs… - Biochemical …, 1994 - Elsevier
A series of quinoline derivatives were analysed for the influence on leukotriene synthesis as
a parameter for 5-LOX (EC 1.13.11.34) activity in a cell-free system of the 10,000g …

(R)-2-[4-(quinolin-2-yl-methoxy) phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human …

…, X Norel, R Müller-Peddinghaus, KH Mohrs… - … of Pharmacology and …, 1994 - ASPET
Anti-IgE at a fixed dilution (1:1000) contracted human airways that had been pretreated with
atropine (1 microM), indomethacin (3 microM) and chlorpheniramine (1 microM). This …

Ca2+ ionophore A23187-stimulated secretion of azurophil granules in human polymorphonuclear leukocytes is largely mediated by endogenously formed leukotriene …

A Hatzelmann, R Fruchtmann, KH Mohrs… - Biochemical …, 1994 - Elsevier
The mode of action of the new leukotriene synthesis inhibitor BAY X1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl
acetic acid) and structurally-related quinoline …

Role of 5-lipoxygenase-activating protein in the regulation of 5-lipoxygenase activity in human neutrophils

R Kast, R Fruchtmann, R Kupferschmidt, KH Mohrs… - Agents and Actions, 1994 - Springer
Using intact and fractionated human polymorphonuclear leukocytes (PMNL), we provide
evidence that the enantioselective leukotriene synthesis inhibitor (LSI) BAY X 1005, (R)-2-[4-(…

[CITATION][C] Fam. Chrysomelidae

KH Mohr - Die Kafer Mitteleuropa, 1966 - cir.nii.ac.jp
MOHR KH. …